This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

UCB3491

UCB SA

Drug Names(s): Radiprodil, RGH-896, UCB-3491, RGH896

Description: RGH-896 is an orally active selective NR2B antagonist. NR2B, a type of NMDA (N-methyl-D-aspartate) receptor, is predominantly expressed on pain processing neuronal pathways. By blocking NR2B, RGH-896 and related compounds block pain signaling without interacting with other NMDA receptor subtypes thus potentially improving therapeutic index and side effect profile.

Deal Structure: Gedeon Richter and Forest
In November 2005, Gedeon Richter and Forest Laboratories entered into a new collaboration agreement that builds upon the existing collaboration announced in 2004. Forest will pay Richter undisclosed upfront and milestone payments in addition to royalties and will have exclusive rights in the U.S. and Canada. The two companies will jointly fund the development program.

Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).

In July 2014, Actavis announced that it has completed the acquisition of Forest in a cash and equity transaction currently valued at approximately $28 billion.

Actavis and Allergan
In June 2015, Actavis...See full deal structure in Biomedtracker


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug